Activities of SYK and PLCγ2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib
Intracellular Signaling Peptides and Proteins
Leukemia, Lymphocytic, Chronic, B-Cell
Phospholipase C gamma
Thus, SYK inhibition predicts cellular response to dasatinib. SYK, together with phospholipase Cgamma2, may serve as potential biomarkers to predict dasatinib therapeutic response in patients. From the pathogenic perspective, our study suggests the existence of alternative mechanisms or pathways that activate SYK, independent of SRC kinase activities. The study further implicates that SYK might serve as a more effective therapeutic target in CLL treatment.